USRE38102E1 - Use of a pyridazinone derivative - Google Patents

Use of a pyridazinone derivative Download PDF

Info

Publication number
USRE38102E1
USRE38102E1 US09/858,482 US85848201A USRE38102E US RE38102 E1 USRE38102 E1 US RE38102E1 US 85848201 A US85848201 A US 85848201A US RE38102 E USRE38102 E US RE38102E
Authority
US
United States
Prior art keywords
methyl
acetamide
oxo
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/858,482
Inventor
Heimo Haikala
Piero Pollesello
Juha Kaivola
Jouko Levijoki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Priority to US09/858,482 priority Critical patent/USRE38102E1/en
Application granted granted Critical
Publication of USRE38102E1 publication Critical patent/USRE38102E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Definitions

  • the intention invention relates to a method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure by administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide to a mammal in need of such treatment.
  • Racemic N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide (I) has been described earlier as a hypotensive agent (U.S. Pat. No. 3,746,712) and as a cardiotonic agent having inotropic activity (U.S. Pat. No. 4,397,854). It has been reported that the inotropic action of racemic N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide is based on phosphodiesterase III (PDE III) enzyme inhibition (Ishimori t.
  • PDE III phosphodiesterase III
  • the compound (I) has an asymmetric carbon atom and may therefore exist in two stereoisomeric forms.
  • the (R)- and (S)- enantiomers of (I) has been earlier described in Japanese patent application no. (Heisei) JP 3163050. However, biological activity data for the enantiomers has not been described.
  • inotropic compounds e.g. milrinone
  • the mechanism of which is based on PDE III inhibition are in clinical trials for the treatment of heart failure.
  • These compounds increase the contractility of the cardiac muscle by increasing the calcium current into the cardiac muscle and produce vasodilatation.
  • the contraction in cardiac muscle is triggered by the binding of calcium in troponin.
  • the main mechanism to increase cardiac contractility should be a mechanism which does not produce calcium overload.
  • the enhancement of the turnover of intracellular calcium released from sarcoplasmic reticulum and the increase of calcium sensitivity of contractile proteins are such mechanisms which do not induce calcium overload.
  • the contractility of the cardiac muscle can still be maintained through neurohumoral activation in the body, which increases the intake of calcium in the cardiac muscle.
  • the calcium overload can trigger arrhythmias, and prolonged neurohumoral activation will accelerate the development of heart failure.
  • Neurohumoral imbalance can be indicated, for example, by altered renin and noradrenaline concentrations in a patient's plasma.
  • PDE III inhibitors can not be used chronically in the treatment of neurohumoral imbalance because they further increase the intake of calcium into the cardiac muscle.
  • the use of a calcium sensitizer can sufficiently increase the contractility already in normal and decreased calcium concentrations which would reduce the need of neurohumoral activation and thereby prevent the development of heart failure.
  • the present invention relates to a method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure by administering orally or parenterally in a solid or liquid dosage form an effective amount of (R)-enantiomer of compound (I) to a patient in need of such treatment.
  • the pharmaceutically active compound according to this invention is formulated into dosage forms using the principles known in the art. It is given to a patient as such or in combination with suitable pharmaceutical excipients in the form of tablets, dragees, capsules, suppositories, emulsions, suspensions or solutions.
  • the composition according to the invention contains a therapeutically effective amount of the pharmaceutically active compound of the invention. The contents of the active compound is in the composition from about 0.5 to 100% per weight.
  • the compound of the invention may be administered to man in oral doses ranging from about 0.1 to 500 mg, preferably 0.5 to 10 mg, per day.
  • suitable ingredients for the composition is a routine for those of ordinary skill in the art. It is evident that suitable carriers, solvents, gel forming ingredients, dispersion forming ingredients, antioxidants, colours, sweeteners, wetting compounds and other ingredients normally used in this field of technology may be also used.
  • Compound A is (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide.
  • the sonicated and dissected fibers were kept for 30 min in a “skinning” solution (ice-cold) containing saponin (250 ⁇ g/ml) in addition to the other constituents. Continuous magnetic stirring was used during this treatment.
  • the fibers which were further dissected ( ⁇ 100 ⁇ m in diameter) were then mounted horizontally with a glue (cellulose acetate in acetone) between a steel-rod extension of isometric force transducer (AME-801 strain gauge, Horten Electronics, Norway) and a glass rod attached to a micro-manipulator.
  • the force transducer was connected to an amplifier.
  • the fibers were kept in the “relaxing” solution containing (mM): imidazole 30, ATP-Na 2 10, NaN 3 5, EGTA 5, MgCl 2 12.5, and 350 U creatinkinase.
  • the temperature of the solution was 22° C. and the pH was set to 6.7 by 1 M KOH.
  • the ionic strength was adjusted with 1 M KCl to correspond that of the “activating” solution.
  • the composition of the “activating” solution was the same as that of the “relaxing” solution except that it contained also CaCl 2 .
  • the fibers were induced to contract in desired free pCas ( ⁇ log [Ca 2+ ]) which were obtained by properly mixing of the “relaxing” and “activating” solutions. Tension produced by a fiber at pCa 4.8 was taken as maximum response. At the beginning of the experiment the fiber was stretched as described above.
  • modified Tyrode solution (37° C.) bubbled with 95% O 2 , 5% CO 2 .
  • the composition of the modified Tyrode solution was (mM): NaCl 135; MgCl 2 .6H 2 O 1; KCl 5; CaCl2.2H 2 O 2; NaHCO 3 15; Na 2 HPO 4 .2H 2 O 1; glucose 10; pH 7.3-7.4.
  • the volume of the open horizontal chamber was 1 ml and flow rate of the superfusion solution running through the chamber was 5 ml/min.
  • Papillary muscle ( ⁇ 1 mm in diameter) was stretched horizontally between force-displacement transducer (FT 0.3 and a needle fixed to the bottom of the chamber.
  • An initial stretching tension of 300 mg was applied to the muscle which was electrically stimulated (Stimulator model SEC 48 F, Grass Instruments) via platinum field electrodes at 1 Hz with rectangular pulses (duration 4 ms).
  • the stimulation occurred at twice threshold voltage in order to achieve simultaneous activation of all myocytes in the capillary muscle.
  • a force-displacement transducer was connected to a polygraph D.C. driver amplifier (model 7 DA, Grass Instruments) and a programmable scanner (model SI 5010, Tetronix).
  • the amplified signal was digitised with 1 kHz frequency by a programmable digitizer (model 390 A, Sony Tetronix).

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure comprises administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide to a mammal in need of such treatment.

Description

The intention invention relates to a method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure by administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide to a mammal in need of such treatment.
Racemic N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide (I) has been described earlier as a hypotensive agent (U.S. Pat. No. 3,746,712) and as a cardiotonic agent having inotropic activity (U.S. Pat. No. 4,397,854). It has been reported that the inotropic action of racemic N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide is based on phosphodiesterase III (PDE III) enzyme inhibition (Ishimori t. et al., Arzneim.-Forsch. (1994) 44(5), 583-8). The compound (I) has an asymmetric carbon atom and may therefore exist in two stereoisomeric forms. The (R)- and (S)- enantiomers of (I) has been earlier described in Japanese patent application no. (Heisei) JP 3163050. However, biological activity data for the enantiomers has not been described.
At the moment series of inotropic compounds, e.g. milrinone, the mechanism of which is based on PDE III inhibition are in clinical trials for the treatment of heart failure. These compounds increase the contractility of the cardiac muscle by increasing the calcium current into the cardiac muscle and produce vasodilatation. The contraction in cardiac muscle is triggered by the binding of calcium in troponin. However, it is possible that the long-term application of PDE III inhibitors leads to calcium overload in the cardiac muscle which can trigger arrhythmias. Therefore, the main mechanism to increase cardiac contractility should be a mechanism which does not produce calcium overload. The enhancement of the turnover of intracellular calcium released from sarcoplasmic reticulum and the increase of calcium sensitivity of contractile proteins are such mechanisms which do not induce calcium overload.
When a patient has harmful alterations in the cardiac function, the contractility of the cardiac muscle can still be maintained through neurohumoral activation in the body, which increases the intake of calcium in the cardiac muscle. In this situation the calcium overload can trigger arrhythmias, and prolonged neurohumoral activation will accelerate the development of heart failure. Neurohumoral imbalance can be indicated, for example, by altered renin and noradrenaline concentrations in a patient's plasma. PDE III inhibitors can not be used chronically in the treatment of neurohumoral imbalance because they further increase the intake of calcium into the cardiac muscle. However, the use of a calcium sensitizer can sufficiently increase the contractility already in normal and decreased calcium concentrations which would reduce the need of neurohumoral activation and thereby prevent the development of heart failure.
It has been now discovered that the (R)-enantiomer of N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide has a calcium sensitizing effect on troponin and that its main mechanism to increase cardiac contractility is the increase of calcium sensitivity of troponin. This was unexpected since the mechanism of rasemic compound (I) was reported to be PDE III inhibition. Thus, being a calcium sensitizer the (R)-enantiomer of N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide has a utility in the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure.
The present invention relates to a method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure by administering orally or parenterally in a solid or liquid dosage form an effective amount of (R)-enantiomer of compound (I) to a patient in need of such treatment.
The pharmaceutically active compound according to this invention is formulated into dosage forms using the principles known in the art. It is given to a patient as such or in combination with suitable pharmaceutical excipients in the form of tablets, dragees, capsules, suppositories, emulsions, suspensions or solutions. The composition according to the invention contains a therapeutically effective amount of the pharmaceutically active compound of the invention. The contents of the active compound is in the composition from about 0.5 to 100% per weight.
In the claimed method the compound of the invention may be administered to man in oral doses ranging from about 0.1 to 500 mg, preferably 0.5 to 10 mg, per day. Choosing suitable ingredients for the composition is a routine for those of ordinary skill in the art. It is evident that suitable carriers, solvents, gel forming ingredients, dispersion forming ingredients, antioxidants, colours, sweeteners, wetting compounds and other ingredients normally used in this field of technology may be also used.
The following example will further illustrate the invention.
EXAMPLE 1 Preparation of (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide
(R)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone (30.0 g) and acetonitrile (600 ml) were mixed and the mixture was refluxed until the starting material dissolves. Acetic anhydride (30.0 ml) was added to the refluxing mixture. After 10 min the solution was allowed to cool to room temperature. The product was filtered, washed with acetonitrile and dried.
Yield 30.8 g, mp 230-232, 1H-NMR (DMSO-d6, 400 MHz) 1.06 (d, 3H, J=7.3 Hz), 2.06 (s, 3H), 2.22 (d, 1H, J=16.6 Hz), 2.67 (dd, 1H, J=16.6 Hz, 6.8 Hz), 3.35 (m, 1H), 7.63 (d, 2H, J=8.8 Hz), 7.72 (d, 2H, J=8.8 Hz), 10.09 (s, 1H), 10.88 (s, 1H). [α]D 20=−466° (c=2 mg/ml, DMF).
The usefulness of the compound of the invention is demonstrated by the following experiments. Compound A is (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide.
Calcium Sensitizing Effect in Skinned Cardiac Fiber
Left ventricular papillary muscle of the guinea-pig was dissected and rinsed in ice-cold Tyrode solution. Thereafter the papillary muscle was immersed into a solution containing (mM): Potassium acetate 74.7, EGTA 10, MgSO4 5.4, ATP-Na2 4, DTE 1, MOPS 20, pH 7.0 (by 1 M KOH). Subsequently, the papillary muscle was sonicated at 10 Watt for 60 sec in this ice-cold solution. The distance between ultrasound probe and the papillary muscle was 10 mm. The fibers (<200 μm in diameter) were dissected from surface of sonicated papillary muscles. Moreover, the sonicated and dissected fibers were kept for 30 min in a “skinning” solution (ice-cold) containing saponin (250 μg/ml) in addition to the other constituents. Continuous magnetic stirring was used during this treatment.
The fibers which were further dissected (<100 μm in diameter) were then mounted horizontally with a glue (cellulose acetate in acetone) between a steel-rod extension of isometric force transducer (AME-801 strain gauge, Horten Electronics, Norway) and a glass rod attached to a micro-manipulator. The force transducer was connected to an amplifier. The fibers were kept in the “relaxing” solution containing (mM): imidazole 30, ATP-Na2 10, NaN3 5, EGTA 5, MgCl2 12.5, and 350 U creatinkinase. The temperature of the solution was 22° C. and the pH was set to 6.7 by 1 M KOH. The ionic strength was adjusted with 1 M KCl to correspond that of the “activating” solution. The composition of the “activating” solution was the same as that of the “relaxing” solution except that it contained also CaCl2. The fibers were induced to contract in desired free pCas (−log [Ca2+]) which were obtained by properly mixing of the “relaxing” and “activating” solutions. Tension produced by a fiber at pCa 4.8 was taken as maximum response. At the beginning of the experiment the fiber was stretched as described above.
TABLE 1
Calcium sensitizing effect in skinned fiber at pCa 5.6
Change in force
% of control
Compound A 0.3 μM + 26 ± 6 (n = 7)
  3 μM + 109 ± 35 (n = 7)
Milrinone ineffective
Positive Inotropic Effect in Paced Cardiac Muscle
Four weeks old guinea-pigs weighing about 350 g were used. In the experiments the right ventricular papillary muscle of the heart was mounted for measurement of isometric tension in organ bath containing modified Tyrode solution (37° C.) bubbled with 95% O2, 5% CO2. The composition of the modified Tyrode solution was (mM): NaCl 135; MgCl2.6H2O 1; KCl 5; CaCl2.2H2O 2; NaHCO3 15; Na2HPO4.2H2O 1; glucose 10; pH 7.3-7.4. The volume of the open horizontal chamber was 1 ml and flow rate of the superfusion solution running through the chamber was 5 ml/min. Papillary muscle (<1 mm in diameter) was stretched horizontally between force-displacement transducer (FT 0.3 and a needle fixed to the bottom of the chamber. An initial stretching tension of 300 mg was applied to the muscle which was electrically stimulated (Stimulator model SEC 48 F, Grass Instruments) via platinum field electrodes at 1 Hz with rectangular pulses (duration 4 ms). The stimulation occurred at twice threshold voltage in order to achieve simultaneous activation of all myocytes in the capillary muscle. A force-displacement transducer was connected to a polygraph D.C. driver amplifier (model 7 DA, Grass Instruments) and a programmable scanner (model SI 5010, Tetronix). The amplified signal was digitised with 1 kHz frequency by a programmable digitizer (model 390 A, Sony Tetronix).
TABLE 2
Positive inotropic effect in guinea-pig papillary muscle
EC50/μM
Compound A 0.1
Milrinone 2

Claims (8)

We claim:
1. A method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure by administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide to a mammal in need of such treatment.
2. The method according to claim 1, wherein said compound is administered to a human in oral doses ranging from 0.1 to 500 mg per day.
3. The method according to claim 2, wherein said compound is administered in oral doses ranging from 0.5 to 10 mg per day.
4. A method of increasing calcium sensitivity of troponin, which method comprises administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahyro-4-methyl-6-oxo-3pyridazinyl)phenyl]acetamide to a mammal.
5. The method acording to claim 4, wherein said compound is administered to a human in oral doses ranging from 0.1 to 500 mg per day.
6. The method according to claim 5, wherein said compound is administered in oral doses ranging from 0.5 to 10 mg per day.
7. A method of increasing calcium sensitivity of contractile proteins of cardiac muscle in a mammal, which method comprises administering an effective amount of (R)-N-[ 4 -( 1,4,5,6 -tetrahydro- 4 -methyl- 6 -oxo- 3 -pyridazinyl)phenyl]acetamide to the mammal.
8. A method for reducing the need for neurohumoral activation in a patient, which comprises administering to the patient an effective amount of (R)-N-[ 4 -( 1,4,5,6 -tetrahydro- 4 -methyl- 6 -oxo- 3 -pyridazinyl)phenyl]acetamide.
US09/858,482 1998-06-19 2001-05-17 Use of a pyridazinone derivative Expired - Lifetime USRE38102E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/858,482 USRE38102E1 (en) 1998-06-19 2001-05-17 Use of a pyridazinone derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/099,945 US5905078A (en) 1998-06-19 1998-06-19 Use of a pyridazinone derivative
US09/858,482 USRE38102E1 (en) 1998-06-19 2001-05-17 Use of a pyridazinone derivative

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/099,945 Reissue US5905078A (en) 1998-06-19 1998-06-19 Use of a pyridazinone derivative

Publications (1)

Publication Number Publication Date
USRE38102E1 true USRE38102E1 (en) 2003-04-29

Family

ID=22277351

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/099,945 Expired - Lifetime US5905078A (en) 1998-06-19 1998-06-19 Use of a pyridazinone derivative
US09/858,482 Expired - Lifetime USRE38102E1 (en) 1998-06-19 2001-05-17 Use of a pyridazinone derivative

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/099,945 Expired - Lifetime US5905078A (en) 1998-06-19 1998-06-19 Use of a pyridazinone derivative

Country Status (18)

Country Link
US (2) US5905078A (en)
EP (1) EP1087769B1 (en)
JP (1) JP4938928B2 (en)
AT (1) ATE261305T1 (en)
AU (1) AU760379B2 (en)
BR (1) BR9911237A (en)
CA (1) CA2334910C (en)
CZ (1) CZ295283B6 (en)
DE (1) DE69915475T2 (en)
EE (1) EE04658B1 (en)
ES (1) ES2217767T3 (en)
HU (1) HUP0202836A3 (en)
IL (2) IL140032A0 (en)
NZ (1) NZ508444A (en)
PL (1) PL194344B1 (en)
SK (1) SK285004B6 (en)
TR (1) TR200003772T2 (en)
WO (1) WO1999066932A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180895A1 (en) * 2001-07-04 2004-09-16 Heimo Haikala Use of a pyridazinone derivative
US20080255134A1 (en) * 2004-11-30 2008-10-16 Artesian Therapeutics, Inc. Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
US8418825B2 (en) 2010-10-28 2013-04-16 Ford Global Technologies, Llc Magnetically actuated mechanical diode
US9366298B2 (en) 2010-10-28 2016-06-14 Ford Global Technologies, Llc Magnetically actuated clutch assembly
US9915301B2 (en) 2010-10-28 2018-03-13 Ford Global Technologies, Llc Magnetically actuated mechanical diode

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20040674A0 (en) 2004-05-12 2004-05-12 Orion Corp A method of inhibiting thromboembolic diseases
TW200920371A (en) 2007-08-29 2009-05-16 Orion Corp A combination treatment
WO2011027021A1 (en) 2009-09-01 2011-03-10 Orion Corporation A method for the treatment of hypertension
WO2021001601A1 (en) 2019-07-01 2021-01-07 Orion Corporation Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3746712A (en) 1971-06-08 1973-07-17 A Ross 6-(substituted-phenyl)-5-methyl-4,5-dihydro-3(2h)-pyridazinones
JPS588015A (en) 1981-07-06 1983-01-18 Mitsubishi Chem Ind Ltd Cardiotonic drug
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
JPH03163050A (en) 1989-07-14 1991-07-15 Teikoku Hormone Mfg Co Ltd Optically active butyric acid derivative
JPH04368328A (en) 1991-06-12 1992-12-21 Teikoku Hormone Mfg Co Ltd Treating agent for chronic cardiac insufficiency
JP3163050B2 (en) 1997-12-25 2001-05-08 三洋電機株式会社 Automatic hair washer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB9606474D0 (en) * 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3746712A (en) 1971-06-08 1973-07-17 A Ross 6-(substituted-phenyl)-5-methyl-4,5-dihydro-3(2h)-pyridazinones
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
JPS588015A (en) 1981-07-06 1983-01-18 Mitsubishi Chem Ind Ltd Cardiotonic drug
JPH03163050A (en) 1989-07-14 1991-07-15 Teikoku Hormone Mfg Co Ltd Optically active butyric acid derivative
JPH04368328A (en) 1991-06-12 1992-12-21 Teikoku Hormone Mfg Co Ltd Treating agent for chronic cardiac insufficiency
JP3163050B2 (en) 1997-12-25 2001-05-08 三洋電機株式会社 Automatic hair washer

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
Bakewell et al., "Inotropic, vasodilator and low Km, cAMP-selective, cGMP-inhibited phosphodiesterase (PDE III) inhibitory activities of 4a-methyl-4,4a-dihydro-5H-indeno[1,2-c]pyridazin-3(2H)-ones and 4a-methyl-4,4a,5,6-tertrahydrobenzo[h]cinnolin-3(2H)-ones", Eur. J. Med. Chem., vol. 25, pp. 765-774 (1990).
David Robertson et al., "Dihydropyridazinone Cardiotonics: The Discovery and Inotropic Activity of 1,3-Dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one1,2", J. Med. Chem., vol. 29, pp. 1832-1840 (1986).
David Robertson et al., "Imidazole-Pyridine Bioisosterism: Comparison of the Inotropic Activities of Pyridine- and Imidazole-Substituted 6-Phenyldihydropyridazinone Cardiotonics", J. Med. Chem., vol. 31, pp. 461-465 (1988).
Derwent Abstract of JP 3163050 A (1991).
Derwent Abstract of JP 4368328 A (1992).
Derwent Abstract of JP 58008015 (1991).
Ishimori et al., "Cardiac Effects of the Novel Pyridazinone Derivative 6-[4-[2-[3-(5-Chloro-2-cyanophenoxy)-2-hydroxypropylamino]-2-methylpropylamino] phenyl]-4,5-dihydro-5-methyl-3 (2H) pyridazinone Monoethyl Maleate and Its Metabolite in Isolated Heart Preparations of Guinea Pigs and Dogs", Arzneim.-Forsch./Drug Res., vol. 44(I)-Nr. 5, pp. 583-588 (1994).
Mohan et al., "Electric field mapping and structure-activity relationships for some dihydropyridazinone cardiotonics", J. of Molecular Structure, vol. 332, pp. 171-176 (1995).
Myasaka, K. et al., "A pyridazinone for treatment of chronic heart failure", Chemical Abstracts abstract of Japanese Patent Application JP 4368328 published Dec. 21, 1992, CA 118:198216.
Sircar et al., "Cardiotonic agents. 10. Cardiovascular evaluation of dihydropyridazinone ring open analogues of imazodan", Eur. J. Med. Chem., vol. 24, pp. 349-355 (1989).
Teikoku Hormone Mgf Co Ltd, "Agent for treating chronic renal failure-contains 6-(4-acetyl-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone", Derwent WPI abstract of Japanese Patent Application JP 4368328 published Dec. 21, 1992, Derwent Info Ltd., Week 9314.
Teikoku Hormone Mgf Ltd. "Novel optically active butyric acid deriv.-obtd. by catalytically hydrogenating butenoic acid derivs., in presence of ruthenium (II) complex(es) for use in pharmaceuticals", Derwent WPI abstract of Japanese Patent Application JP 3163050 published Jul. 15, 1991, Derwent Info Ltd., Week 9134.
Toshimi Seki et al., "Studies on Agens with Vasodilator and beta-Blocking Activities. V. 1)Synthesis and Pharmacological Activity of the Optical Isomers of TZC-5665", Chem. Pharm. Bull, vol. 46 (1), pp. 84-96 (1998).
Toshimi Seki et al., "Studies on Agens with Vasodilator and β-Blocking Activities. V. 1)Synthesis and Pharmacological Activity of the Optical Isomers of TZC-5665", Chem. Pharm. Bull, vol. 46 (1), pp. 84-96 (1998).
William Coates et al., "1,4-Bis (3-oxo-2,3-dihydropyridazin-6-yl) benzene Analogues: Potent Phosphodiesterase Inhibitors and Inodilators", J. Med. Chem., vol. 33, pp. 1735-1741 (1990).
Yasuda, K. et al., "Preparation of optically active aminobenzoylbutyric acid derivatives as intermediates for beta.-blockers and antihypertensives", Chemical Abstracts abstract of Japanese Patent Application JP 3163050 published Jul. 15, 1991, CA 116: 106784.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180895A1 (en) * 2001-07-04 2004-09-16 Heimo Haikala Use of a pyridazinone derivative
US20080255134A1 (en) * 2004-11-30 2008-10-16 Artesian Therapeutics, Inc. Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
US8418825B2 (en) 2010-10-28 2013-04-16 Ford Global Technologies, Llc Magnetically actuated mechanical diode
US9366298B2 (en) 2010-10-28 2016-06-14 Ford Global Technologies, Llc Magnetically actuated clutch assembly
US9915301B2 (en) 2010-10-28 2018-03-13 Ford Global Technologies, Llc Magnetically actuated mechanical diode

Also Published As

Publication number Publication date
HUP0202836A3 (en) 2003-03-28
NZ508444A (en) 2003-03-28
PL345036A1 (en) 2001-11-19
PL194344B1 (en) 2007-05-31
DE69915475T2 (en) 2005-03-24
TR200003772T2 (en) 2001-06-21
WO1999066932A1 (en) 1999-12-29
AU760379B2 (en) 2003-05-15
IL140032A0 (en) 2002-02-10
AU4516699A (en) 2000-01-10
IL140032A (en) 2007-05-15
CZ20004554A3 (en) 2001-05-16
HUP0202836A2 (en) 2003-02-28
CZ295283B6 (en) 2005-06-15
EP1087769B1 (en) 2004-03-10
EE04658B1 (en) 2006-08-15
DE69915475D1 (en) 2004-04-15
ATE261305T1 (en) 2004-03-15
JP4938928B2 (en) 2012-05-23
SK18732000A3 (en) 2001-12-03
EE200000755A (en) 2002-04-15
BR9911237A (en) 2001-03-06
CA2334910C (en) 2007-10-23
CA2334910A1 (en) 1999-12-29
SK285004B6 (en) 2006-04-06
ES2217767T3 (en) 2004-11-01
EP1087769A1 (en) 2001-04-04
JP2002518450A (en) 2002-06-25
US5905078A (en) 1999-05-18

Similar Documents

Publication Publication Date Title
JP2879910B2 (en) Novel 4H-1-benzopyran-4-one derivatives
US6649628B1 (en) N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
JP3621102B2 (en) Novel enzyme inhibitors, their synthesis and methods of use
USRE38102E1 (en) Use of a pyridazinone derivative
EP3858827A1 (en) Preparation of semicarbazide-sensitive amine oxidase inhibitor and use thereof
CA2974726C (en) Imidazolyl tricyclic enones as antioxidant inflammation modulators
KR101021042B1 (en) Pharmaceutical composition comprising sulfonylaminocarboxylic acid N-arylamide as guanylate cyclase activator
US20250059154A1 (en) Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
US20030109570A1 (en) Benzothiophene derivatives and medicinal use thereof
RU2130019C1 (en) Derivatives of 3(2)-pyridazinone, a pharmaceutical composition, a method of treatment
US4562196A (en) 2,4-Diaminopyridine as a pharmacologic agent
JPH072831A (en) Aminocycloalkanobenzodioxole as beta-3-selective adrenergic agent
JPS62289525A (en) Calcium modulative compound and pharmaceutical composition
CN101374839A (en) Azindoles useful as Janus kinase inhibitors
EP0802900B1 (en) Antiarrhythmic (s)-enantiomers of methanesulfonamides
US5874475A (en) Antiarrhythmic (S)-enantiomers of methanesulfonamides
JP4722325B2 (en) Subtype-selective adenylate cyclase activator
JPH0193567A (en) 2,6-acetoxylidide derivative
KR910004674B1 (en) Arrhythmia Treatment
JPH11222474A (en) Diabetes treatment
HU209446B (en) Process for preparing pharmaceutical compositions containing n,n- -dibenzyl-aminobutiric acid and its derivatives as active agent
CA2196064A1 (en) 4-(4-methanesulfonamidophenyl)butylamine derivatives with antiarrhythmic activity
HK1247609A1 (en) Imidazolyl tricyclic enones as antioxidant inflammation modulators
JPH07304671A (en) Therapeutic agent for symptoms induced by peripheral circulatory disorder
GB2195631A (en) Quinolone cardiac stimulants

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12